tbuckley/cabot-search huggingface dataset:
AB0269 Cardiovascular Risk Assessment in Persons with Autoimmune Rheumatic Disease: A Pilot Study of Non-Invasive Arterial Health Testing
Authors: E.M. Scanlon, R. Mankad, C.S. Crowson, I.J. Kullo, S.L. Mulvagh, E.L. Matteson, Z. Kvrgic, J.M. Davis
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Persons with rheumatoid arthritis (RA) have increased mortality attributable to atherosclerotic cardiovascular disease (ASCVD) events. While a heightened risk of ASCVD events exists in patients with RA, we have yet to uncover an accurate method for estimating that risk. It is unknown how the current state of disease activity affects arterial function in early subclinical ASCVD. <h3>Objectives</h3> Our goal is to determine the effect of the current state of inflammatory disease activity, as measured by the Simplified Disease Activity Index (SDAI) and Health Assessment Questionnaire (HAQ) score, on arterial health in patients with RA, using an innovative non-invasive testing package developed at Mayo Clinic in Rochester, Minnesota. <h3>Methods</h3> We recruited a cohort of 50 patients with RA as defined by the 2010 American College of Rheumatology/European League Against Rheumatism classification criteria, and conducted non-invasive arterial health testing on the same day as a rheumatologic assessment of clinical disease activity, which was classified in terms of tender/swollen joint counts, SDAI score and HAQ score. This arterial health testing package includes measurements of endothelial function (brachial artery reactivity testing, BART), arterial stiffness (pulse wave velocity, PWV), and early atherosclerosis (carotid intima-media thickness, CIMT, and carotid plaque presence). Statistical analysis was performed with Spearman Correlation Coefficients between the rheumatologic disease activity scores and arterial health testing parameters. <h3>Results</h3> Our 50 patients had mean (SD) disease duration of 7.0 (±4.0) years, mean age of 57.2 years, and 38 (76%) were female. The average disease activity was moderate, with mean (SD) SDAI of 21.4 (±17.4); 27 patients had either moderate or high disease activity by SDAI. A statistically significant correlation emerged between the SDAI score and the following measures: corrected aortic augmentation index (r=0.35, p=0.012); and the CIMT of the right common carotid artery (r=0.28, p=0.048). The correlation between SDAI and aortic PWV was borderline (r=0.26, p=0.067). The HAQ score correlated significantly with the corrected aortic augmentation index (r=0.33, p=0.019), but not with PWV or CIMT measures of right and left common carotid artery. <h3>Conclusions</h3> We identified significant correlations between SDAI, and measures of arterial stiffness (i.e., corrected aortic augmentation index), and subclinical atherosclerosis (i.e., CIMT). The HAQ score significantly correlated with the corrected aortic augmentation index. This study suggests that the current state of disease activity in RA does significantly influence several measures of arterial health using this testing package. <h3>Disclosure of Interest</h3> None declared
Comparison between Widefield En Face Swept-Source OCT and Conventional Multimodal Imaging for the Detection of Reticular Pseudodrusen
Authors: Karen B. Schaal, Andrew D. Legarreta, William J. Feuer, Giovanni Gregori, Qianqian Cheng, John E. Legarreta, Mary K. Durbin, Paul F. Stetson, Sophie Kubach, Philip J. Rosenfeld
Journal: Ophthalmology (2016)
Impact of Rituximab-Based Immunochemotherapy Induction and Maintenance on the Immunisation Rate Against Tetanus Toxin in Follicular Lymphoma Treated Patients : A Subanalysis of the PRIMA Study
Authors: Lionel Karlin, Jacques Bienvenu, Rene-Olivier Casasnovas, Marie-Helene Delfau-Larue, Pierre Feugier, Jehan Dupuis, Tioka Rabeony, Christophe Ferme, Catherine Sebban, Pierre Soubeyran, Guillaume Cartron, Alain Delmer, Dominique Bordessoule, Pauline Brice, Thierry Lamy, Sami Bousseta, Hervé Tilly, Gilles Andre Salles
Journal: Blood (2014)
Histone Deacetylase Inhibitor Depsipeptide (FK228) Induces Apoptosis in Leukemic Cells by Facilitating Mitochondrial Translocation of Bax, Which Is Enhanced by Proteasome Inhibitor Bortezomib.
Authors: Krittaya Sutheesophon, Yukiko Kobayashi, Masa-aki Takatoku, Keiya Ozawa, Yasuhiko Kano, Hideshi Ishii, Yusuke Furukawa
Journal: Blood (2005)
In Vitro Assessment of Anti-Multiple Myeloma (MM)-Agents On Various MM-Cell Lines (MMCLs) with Use of Bortezomib, Sorafenib, Thalidomide, Lenalidomide and EpiGalloCatechin-3-Gallate (EGCG) Demonstrates to Be a Valuable Tool for the Thorough Analysis and Discovery of Innovative Anti-MM-Agents.
Authors: Josefina Udi, Dagmar Wider, Gabriele Ihorst, Julia Schüler, Ralph Wäsch, Monika Engelhardt
Journal: Blood (2009)
The Use of Imatinib with Chemotherapy and Allogeneic Hematopoietic Stem Cell Transplantation Improves Survival of Philadelphia Positive Acute Lymphoblastic Leukemia in Adults
Authors: Josefina Perez-Nuñez, Antonio Jimenez-Velasco, Katy Hurst, Manuel Barrios-Garcia, MJ Moreno, Ana Isabel Heiniger Mazo
Journal: Blood (2014)
Parents' and staff's views of adapting the Nutrition and Physical Activity Self-Assessment for Childcare in UK nurseries to improve physical activity and healthy eating
Authors: Rowan Brockman, Russell Jago, James White, Rona Campbell, William Hollingworth, Chris Metcalfe, Angeliki Papadaki, Sian Wells, Dianne Ward, Laurence Moore, Ruth Kipping
Journal: The Lancet (2016)
Autologous CMV-Specific T Cells as Effector Cells in Immunotherapy of B Cell Chronic Lymphocytic Leukemia.
Authors: Arnon P. Kater, Esther E.B.M Remmerswaal, Martijn A. Nolte, Eric Eldering, Rene A.W van Lier, Marinus H.J van Oers
Journal: Blood (2004)
Outcome of Elderly Patients with Acute Myeloid Leukemia (AML) Post Hypomethylating Agent (HMA) Failure.
Authors: Koichi Takahashi, Hagop M. Kantarjian, Hady Ghanem, Farhad Ravandi, Jorge E. Cortes, Tapan M. Kadia, Susan O'Brien, Sherry A. Pierce, Nitin Jain, Guillermo Garcia-Manero, Elias J. Jabbour
Journal: Blood (2012)
PET-CT Scan for Detection of Extramedullary Acute Myeloid Leukemia
Authors: Friedrich Stölzel, Klaus Zoephel, Christoph Röllig, Jörgen Radke, Johannes Schetelig, Uwe Platzbecker, Martin Bornhaeuser, Gerhard Ehninger, Jörg Kotzerke, Markus Schaich
Journal: Blood (2010)
Phase II Multicenter Study of Association of Arsenic Trioxide (ATO) and Ascorbic Acid in Myelodysplastic Syndrome.
Authors: Flavia Salvi, Daniela Gioia, Maria Teresa Corsetti, Anna Maria Pelizzari, Emanuela Messa, Daniela Cilloni, Gianni Cametti, Monica Albanesi, Angelo Colaemma, Filippo Marmont, Ernesta Audisio, Eros Di Bona, Monia Lunghi, Giorgio Ciravegna, Margherita Bonferroni, Alfredo Barbato, Bruno Banconet, Dario Ferrero, Gianluca Gaidano, Andrea Gallamini, Anna Marina Liberati, Enrico Pogliani, Giuseppe Rossi, Giuseppe Saglio, Alessandro Levis
Journal: Blood (2009)
Prediction of Relapse After Discontinuation of Antipsychotic Treatment in Alzheimer’s Disease: The Role of Hallucinations
Authors: Anjali N. Patel, Seonjoo Lee, Howard F. Andrews, Gregory H. Pelton, Susan K. Schultz, David L. Sultzer, Jacobo Mintzer, Danilo de la Pena, Sanjay Gupta, Sylvia Colon, Corbett Schimming, Bruce Levin, D.P. Devanand
Journal: American Journal of Psychiatry (2016)

In Alzheimer's disease, antipsychotic medications are often used for a period, with relief of symptoms, and then discontinued, after which relapse may occur. The authors sought to determine which neuropsychiatric symptoms predict relapse.In the Antipsychotic Discontinuation in Alzheimer's Disease trial, 180 patients with Alzheimer's disease and symptoms of agitation or psychosis were treated with risperidone for 16 weeks, after which patients who responded (N=110) were randomly assigned to continue risperidone for 32 weeks, to continue risperidone for 16 weeks followed by switch to placebo for 16 weeks, or to receive placebo for 32 weeks. As reported previously, discontinuation of risperidone was associated with a two- to fourfold increased risk of relapse over 16-32 weeks. In planned post hoc analyses, the authors examined associations between the 12 symptom domains in the Neuropsychiatric Inventory (NPI) and relapse in the first 16-week phase after randomization.Compared with patients with mild hallucinations or no hallucinations, patients with severe hallucinations as a presenting symptom at baseline had a higher likelihood of relapse (hazard ratio=2.96, 95% CI=1.52, 5.76). This effect was present for the subgroup with auditory hallucinations, but not the subgroup with visual hallucinations. Among patients with baseline hallucinations, 13 of 17 (76.5%) who discontinued risperidone relapsed, compared with 10 of 26 (38.5%) who continued risperidone (p<0.02). This group difference remained significant for severe (77.8%) compared with mild (36%) hallucinations. NPI domain scores after the initial open-treatment phase were not associated with relapse.Patients with severe baseline hallucinations were more likely to relapse after randomization, and the presence of baseline hallucinations was associated with a higher risk of relapse after discontinuation of risperidone compared with continued risperidone treatment. For patients with hallucinations, particularly auditory hallucinations, antipsychotic discontinuation should be approached cautiously because of high relapse risk.
Abstract 2886: Fluvastatin Xl Use Is Associated With Improved Cardiac Outcome After Major Vascular Surgery. Results From A Randomized Placebo Controlled Trial: Decrease III
Authors: Don Poldermans, Olaf Schouten, Rob Benner, Hero van Urk, Hence J Verhagen, Nishar Khan, Harm Feringa, Martin Dunkelgrun, Jeroen J Bax, Eric Boersma
Journal: Circulation (2008)
PTH-081 Allopurinol Abrogates Thiopurine Induced Liver Injury Without The Need for Metabolite Measurments
Authors: P Pavlidis, R Reynolds, A Ansari
Journal: Gut (2016)

<h3>Introduction</h3> The thiopurines azathioprine and mercaptopurine are widely used as long term immunomodulators in inflammatory bowel diseases (IBD). Reported side effects vary between 10–40% hindering the efficacy and safety of these useful treatments. Hepatotoxicity is one of the commoner side effects (up to 10%) and some investigators have made an association to thiopurine methyltransferase (TMPT) levels as well as hypermethylation. <h3>Aim</h3> Report on the use of allopurinol in conjuction to azathioprine (Low Dose Azathioprine Allopurinol- LDAA) in patients who developed thiopurine induced liver injury. <h3>Methods</h3> This is a retrospective cohort study. The patients were drawn from a large database of patients at a single District General Hospital by the authors. The outcomes were assessed by review of patient records. <h3>Results</h3> We identified 15 (10%) patients who developed thiopurine induced liver injury [median (range) ALT: 74 iu/L (49,630), ALP: 35 iu/L (20, 120), bilirubin: 8μmol/L (5, 45), time of onset from drug commencement: 12 weeks (6, 30)] in the last 5 years from a prospective cohort of 150 patients who required azathioprine for IBD (Crohn’s disease: 8, Ulcerative colitis: 7, 1 with concomitant psoriatic arthropathy and 1 with Takayasu’s arteritis). There were 7 (47%) patients with wild type TPMT and 8 (53%) heterozygotes. Seven (78%)of the 9 patients receiving LDAA had a normalisation of aminotransferases after an increase in allopurinol dose from 100 mg to 200 mg while two were eventually diagnosed with primary sclerosing cholangitis. Addition of allopurinol (100 mg) for the 6 patients on azathioprine monotherapy lead to normalisation of aminotransferases. <h3>Conclusion</h3> Observations form this data suggest i) Patients who cannot produce high methylated mercaptopurine metabolites (MMP) can develop hepatotoxicity which responds well to allopurinol. ii) Patients may still develop hepatotoxicity on co-therapy with 100 mg of allopurinol, which responds to a dose increase to 200 mg, suggesting an independent hepatocyte protective effect of allopurinol. We have previously suggested a role for reactive oxygen species. iii) Thiopurine metabolites profiles should not be used to guide allopurinol use, as the protective effect is not predicted by high MMP levels. <h3>Disclosure of Interest</h3> None Declared
Different Levels of Alkaline Phospatase (ALP) in Multiple Myeloma (MM) and SOLID Tumors with BONE Lesions
Authors: Ombretta Annibali, Maria Teresa Petrucci, Daniele Santini, Elisabetta Lisi, MArco Mariani, Francesco Pisani, Velia Bongarzoni, Olga Venditti, Angela Rago, Elisabetta Cerchiara, Alessia Fiorini, Luca Franceschini, Stefano Felici, MArco Russano, Francesco PAntano, Giuseppe Avvisati
Journal: Blood (2015)
TARC and RANTES Enhance Immunological Antitumor Effect Induced by GM-CSF Transduced Leukemia Vaccine in Mouse Model.
Authors: Hiroyuki Inoue, Mutsunori Iga, Meng Xin, Ryo Kurita, Masaharu Nakayama, Yoko Suehiro, Yukoh Nakazaki, Koichi Takayama, Yoichi Nakanishi, Kenzaburo Tani
Journal: Blood (2007)
Hospital Factors Associated With Care Discontinuity Following Emergency General Surgery
Authors: Joaquim M. Havens, Olubode A. Olufajo, Thomas C. Tsai, Wei Jiang, Alexandra B. Columbus, Stephanie L. Nitzschke, Zara Cooper, Ali Salim
Journal: JAMA Surgery (2016)

Although there is evidence that changes in clinicians during the continuum of care (care discontinuity) are associated with higher mortality and complications among surgical patients, little is known regarding the drivers of care discontinuity among emergency general surgery (EGS) patients.To identify hospital factors associated with care discontinuity among EGS patients.We performed a retrospective analysis of the 100% Medicare inpatient claims file, from January 1, 2008, to November 30, 2011, and matched patient details to hospital information in the 2011 American Hospital Association Annual Survey database. We selected patients aged 65 years and older who had the most common procedures associated with the previously defined American Association for the Surgery of Trauma EGS diagnosis categories and survived to hospital discharge across the United States. The current analysis was conducted from February 1, 2016, to March 24, 2016.Care discontinuity defined as readmission within 30 days to nonindex hospitals.There were 109 443 EGS patients readmitted within 30 days of discharge and 20 396 (18.6%) were readmitted to nonindex hospitals. Of the readmitted patients, 61 340 (56%) were female. Care discontinuity was higher among patients who were male (19.5% vs 18.0%), those younger than 85 years old (19.0% vs 16.6%), and those who lived 12.8 km (8 miles) or more away from the index hospitals (23.7% vs 14.8%) (all P < .001). Care discontinuity was independently associated with mortality (adjusted odds ratio [aOR], 1.16; 95% CI, 1.08-1.25). Hospital factors associated with care discontinuity included bed size of 200 or more (aOR, 1.45; 95% CI, 1.36-1.54), safety-net status (aOR, 1.35; 95% CI, 1.27-1.43), and teaching status (aOR, 1.18; 95% CI, 1.09-1.28). Care discontinuity was significantly lower among designated trauma centers (aOR, 0.89; 95% CI, 0.83-0.94) and highest among hospitals in the Midwest (aOR, 1.15; 95% CI, 1.05-1.26).Nearly 1 in 5 older EGS patients is readmitted to a hospital other than where their original procedure was performed. This care discontinuity is independently associated with mortality and is highest among EGS patients who are treated at large, teaching, safety-net hospitals. These data underscore the need for sustained efforts in increasing continuity of care among these hospitals and highlight the importance of accounting for these factors in risk-adjusted hospital comparisons.
FRI0594 Association of Gout Diagnosis with Increased Risk of Joint Replacement: A Population-Based Cohort Study of over 250,000 Patients
Authors: S. Perreault, A.B. Klein, R. Morlock
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Gout is the most common cause of inflammatory arthritis in men and older women, and there are very few studies on the rate of joint replacement among patients with diagnosed gout compared to those without gout. <h3>Objectives</h3> To assess the risk of joint replacement among patients with diagnosed gout compared to patients without gout diagnosis, and the predictors. <h3>Methods</h3> This was a population-based study with cohort study design in a cohort of older adults. We first identified all subjects aged &gt;66 years between January 1, 1995 and December 31, 2009. A study cohort of 252,255 individuals was reconstructed using the Quebec RAMQ and MedEcho administrative databases. Patients with gout diagnosis were defined only if they met <i>all</i> of the following criteria: 1) gout defined by <i>ICD-9 or ICD-10 or exposure of specific gout treatment.</i> The date of cohort entry of patients with gout was defined as the first date of established gout during follow-up. The primary outcome was incident joint replacement rate defined by a composite endpoint representing patients with a medical procedure in the hip, femur and basin, knee, ankle/foot, hand/finger, shoulder and humerus, forearm and elbow, or wrist. Potential predictive factors examined included gout diagnosis, cardiovascular diseases, cerebrovascular disease, peripheral vascular disease, diabetes, kidney disease, pulmonary disease, dementia, rheumatic disease, and gastrointestinal disease. <h3>Results</h3> The incident rate of joint replacements was at 2.67 (95% CI: 2.57–2.77) and 1.92 (1.90–1.94) per 100 person-years among patients with diagnosed gout and those without a gout diagnosis, respectively (p&lt;0.0001). Major predictors of total joint replacements were gout diagnosis (31%), advanced age (42%), cerebrovascular disease (13%), acute renal failure (10%), respiratory disease (12%), rheumatic disease (43%), and gastrointestinal disease (10%). Significant predictors of drug exposure are NSAIDs, intra-articular corticosteroids and narcotic use. Noted limitations included the limited ability to adjust for clinical severity and the potential of residual confounding factors. <h3>Conclusions</h3> Gout disease was associated with a significant, 31% increase risk of joint replacement in older adults. Further research should be conducted to confirm this potential associated risk. <h3>Acknowledgement</h3> This study was funded by AstraZeneca. <h3>Disclosure of Interest</h3> S. Perreault: None declared, A. Klein Employee of: AstraZeneca, R. Morlock Employee of: Ardea Biosciences, Inc., a member of the AstraZeneca Group
Applying the acute:chronic workload ratio in elite football: worth the effort?
Authors: Martin Buchheit
Journal: British Journal of Sports Medicine (2016)

The use of the acute:chronic workload ratio (A/C) has received a growing interest in the past 2 years to monitor injury risk in a variety of team sports.1 ,2 This ratio is generally computed over 28 days (ie, load accumulated during the current week/load accumulated weekly over the past 28 days), using both internal (session-rate of perceive exertion (Session-RPE)×duration) and external (tracking variables, often Global Positioning System (GPS)-related, such as high-speed running and acceleration variables) measures of competitive and training load. While the potential benefit of such a metric is straight forward for practitioners, there remain several limitations to (1) the assessment of relative external load and in turn, injury risk in players differing in locomotor profiles and (2) the effective monitoring of overall load across all training and matches throughout the year. In turn, these limitations likely compromise the usefulness of the A/C ratio in elite football (soccer).

Assessing player's locomotor profile and relative external load. 

1.  Speed : Considering that subtle differences in sprinting intensity such as high (85–95% of maximal sprinting speed) versus very high-speed running (>95%) may have important implications with regard to injury risk and prevention,3 the individualisation of high-speed running zones may be important. However, such a sprint-intensity classification requires the use of players' maximal sprinting speed as a reference, which is very rarely assessed in elite players. Therefore, considering the large variations in locomotor profiles between players within the same team, the use of absolute (fixed) speed thresholds to define high-speed running zones may limit the sensitivity of the A/C ratio with respect to high-speed running load3 and in turn, injury risk.

2.  Fitness : Considering that fitness testing (eg, maximal aerobic speed) is also rare in professional football, and considering the clear impact of fitness on injury risk,4 it is difficult to …
Preliminary Results of Phase I Trial of Sphingosomal Vincristine (SV) and Dexamethasone in Relapsed or Refractory Acute Lymphocytic Leukemia (ALL).
Authors: Deborah A. Thomas, Guillermo Garcia-Maneron, Stefan Faderl, Susan O’Brien, Francis J. Giles, Alessandra Ferrajoli, William Wierda, Srdan Verstovsek, Jorge Cortes, Hagop Kantarjian
Journal: Blood (2004)
No Evidence for Increased Prevalence of JAK2 V617F in Women with a History of Recurrent Miscarriage
Authors: Issa J. Dahabreh, Amy V. Jones, Michael Voulgarelis, Christina Alafakis-Tzannatos, Stavroula Giannouli, Marighoula Varla-Leftherioti, Theodora Keramitsoglou, Christine Zoi, Dimitris Loukopoulos, Stelios Fotiou, Nicholas C.P. Cross, Katerina Zoi
Journal: Blood (2008)
Prospective Observational Study of 110 Multiple Myeloma (MM) Patients On Monthly Versus 3 Monthly Infusion of Zoledronic Acid
Authors: Ashraf Z. Badros, Sunita Philip, Patricia Lesho, Dianna Weikel, Olga Goloubeva, Mariola Sadowska, Rena Lapidus, Lisa Hester, Todd Milliron, Timothy Meiller
Journal: Blood (2012)
Neoadjuvant Enzalutamide Prior to Prostatectomy
Authors: Bruce Montgomery, Maria S. Tretiakova, Anthony M. Joshua, Martin E. Gleave, Neil Fleshner, Glenn J. Bubley, Elahe A. Mostaghel, Kim N. Chi, Daniel W. Lin, Martin Sanda, William Novotny, Kenneth Wu, Philip W. Kantoff, Brett T. Marck, Stephen Plymate, Steven P. Balk, Peter S. Nelson, Alvin M. Matsumoto, Rosina T. Lis, Adam Kibel, Gabriel P. Haas, Andrew Krivoshik, Alison Hannah, Mary-Ellen Taplin
Journal: Clinical Cancer Research (2016)

Purpose: Prostate cancer is dependent on androgen receptor (AR) activation. Optimal AR antagonism may effectively cytoreduce local disease and suppress or eliminate micrometastases. We evaluated neoadjuvant therapy prior to prostatectomy with the potent AR antagonist enzalutamide (enza) either alone or in combination with dutasteride (dut) and leuprolide (enza/dut/luteinizing hormone-releasing hormone analogues [LHRHa]).Experimental Design: Forty-eight of 52 men with intermediate or high-risk localized prostate cancer proceeded to prostatectomy after neoadjuvant enzalutamide or enza/dut/LHRHa for 6 months. We assessed pathologic complete response (pCR), minimal residual disease (MRD; ≤3 mm maximum diameter of residual disease), residual cancer burden (RCB), and expression of PSA and serum and tissue androgen concentrations. We compared the proportion of patients with pCR in each treatment arm with a historical control rate of 5%, based on previous reports of flutamide with LHRHa.Results: In the enzalutamide arm, none of the 25 patients achieved pCR or MRD. In the enza/dut/LHRHa arm, one of 23 patients (4.3%) achieved pCR and 3 of 23 (13.0%) achieved MRD. Median RCB was higher in the enzalutamide arm than in the enza/dut/LHRHa arm (0.41 cm3 vs. 0.06 cm3, respectively). Tissue testosterone and dihydrotestosterone levels correlated with RCB. No adverse events leading to study drug discontinuation were reported.Conclusions: Combination therapy with enza/dut/LHRHa resulted in pCR and MRD rates comparable with historical controls. Evidence of continued AR activity in residual tumor suggests that AR signaling may contribute to survival. Strategies to more effectively ablate AR activity are warranted to determine whether more substantial antitumor effects are observed. Clin Cancer Res; 23(9); 2169-76. ©2016 AACR.
Expression Level of Granulocyte-Colony Stimulating Factor Receptor and Effect of Two Forms of G-CSF to in AML1/ETO+ Acute Myelogenous Leukemia.
Authors: Heewon Moon, Tae Young Kim, Hyun Chung Min, Bo Ra Oh, Sung Soo Yoon, Byoung Kook Kim, Han Ik Cho, D.S. Lee
Journal: Blood (2007)